HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases

Amendment allows for the development of IVD test kits compatible with Illumina technology TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its